drug
as of 2026-07-01atomoxetine
Atomoxetine
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Eli Lilly and Company
5 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Trials
5
The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype
NCT00548327Phase 2Terminated
Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation
NCT00628394Phase 4Completed
Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia
NCT00488163Phase 4Completed
Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia
NCT00161031—Completed
A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia
NCT00089869Phase 1, Phase 2Completed
KOLs & investigators
4
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication
indication
indication
indication
indication
KOL
Carol A Tamminga, MD
personKOL score 9
Joseph I. Friedman, MD
personKOL score 5
Deanna L Kelly, Pharm.D.
personKOL score 5
Jose A Apud, M.D.
personKOL score —